| Amgen Protocol No. 20060362 - A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer
Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information
Basic Trial Information
 |
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
18 and over
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
20060362
NCT00626106
|
|
|
Trial Description
Summary This is a randomized, double-blind, placebo-controlled, phase 2 study. Subjects will include postmenopausal women with confirmed HR-positive, locally advanced or metastatic breast cancer, who have disease progression during or within 12 months after completing prior adjuvant endocrine therapy or during the first prior endocrine therapy for metastatic disease. Eligibility Criteria Inclusion Criteria: - Histologically or cytologically confirmed carcinoma of the breast with locally advanced or metastatic disease
- Confirmation of hormone receptor (HR) positive disease status
- Amenable to receive endocrine therapy
- Disease progression while receiving prior endocrine therapy for locally advanced or metastatic breast cancer
- Postmenopausal woman ≥ 18 years old
Exclusion Criteria: - HR-unknown or HR-negative disease
- Not amenable to endocrine therapy
- Central nervous system metastasis
Trial Contact Information
Trial Lead Organizations/Sponsors Amgen, Incorporated | MD | | Study Director |
| Amgen Call Center | | Ph: 866-572-6436 |
Trial Sites
|
|
|
|
| U.S.A. |
|
| Arizona |
|
| |
Chandler |
|
| | | | | | | | Research Site |
|
| California |
|
| |
Anaheim |
|
| | | | Research Site |
|
| |
Beverly Hills |
|
| | | Research Site |
|
| |
Montebello |
|
| | | Research Site |
|
| |
Pleasant Hill |
|
| | | Research Site |
|
| Connecticut |
|
| |
Stanford |
|
| | | | Research Site |
|
| Florida |
|
| |
Boca Raton |
|
| | | | Research Site |
|
| |
Boynton Beach |
|
| | | Research Site |
|
| |
Coral Springs |
|
| | | Research Site |
|
| |
Gainesville |
|
| | | Research Site |
|
| |
Lake Worth |
|
| | | Research Site |
|
| Georgia |
|
| |
Atlanta |
|
| | | | Research Site |
|
| Illinois |
|
| |
Chicago |
|
| | | | Research Site |
|
| New Hampshire |
|
| |
Lebanon |
|
| | | | Research Site |
|
| New Jersey |
|
| |
Mountain Lakes |
|
| | | | Research Site |
|
| North Carolina |
|
| |
High Point |
|
| | | | Research Site |
|
| Pennsylvania |
|
| |
Hershey |
|
| | | | Research Site |
|
| Tennessee |
|
| |
Memphis |
|
| | | | Research Site |
|
| Utah |
|
| |
American Fork |
|
| | | | Research Site |
|
| Washington |
|
| |
Tacoma |
|
| | | | Research Site |
|
| Australia |
|
| |
Footscray |
|
| | | | Research Site |
|
| |
Geelong |
|
| | | Research Site |
|
| |
Melbourne |
|
| | | Research Site |
|
| New South Wales |
|
| |
Waratah |
|
| | | | Research Site |
|
| South Australia |
|
| |
Woodville |
|
| | | | Research Site |
|
| Canada |
|
| British Columbia |
|
| |
Vancouver |
|
| | | | | Research Site |
|
| Ontario |
|
| |
Ottawa |
|
| | | | Research Site |
|
| |
Toronto |
|
| | | Research Site |
|
| France |
|
| |
Le Mans |
|
| | | | Research Site |
|
| |
Montpellier cedex 5 |
|
| | | Research Site |
|
| |
Paris |
|
| | | Research Site |
|
| |
St Herblain |
|
| | | Research Site |
|
| Ireland |
|
| |
Dublin |
|
| | | | Research Site |
|
| Spain |
|
| |
Barcelona |
|
| | | | Research Site |
|
| |
L'Hospitalet de Llobregat (Barcelona) |
|
| | | Research Site |
|
| |
Madrid |
|
| | | Research Site |
|
| |
Sabadell |
|
| | | Research Site |
|
| Switzerland |
|
| |
Chur |
|
| | | | Research Site |
|
| |
Luzern 16 |
|
| | | Research Site |
|
| |
Zurich |
|
| | | Research Site |
|
Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00626106
Information obtained from ClinicalTrials.gov on October 03, 2008 Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain
the same text. Minor
changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and
contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should
be directed to ClinicalTrials.gov.
Back to Top |
